Investors

Key press releases

04 May 2026
16:30 E.S.T.

Cellectis to Report First Quarter Financial Results on May 11, 2026

27 Apr 2026
10:14 E.S.T.

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

13 Apr 2026
04:30 E.S.T.

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

Key upcoming events

17 Mar 2026

AACR Annual Meeting 2026

Learn more

20 Mar 2026

Cellectis Q4 & full year 2025 earnings call

Learn more

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$3.9150

-0.0350 (-0.8861%)

Prev. close: 3.9500
Volume: 4,536
High: 4.0000
Capitalization: 282.247M

€3.2920

-0.0240 (-0.7238%)

Prev. close: 3.3160
Volume: 159,781
High: 3.4300
Capitalization: 237.332M

See stock information

Covering research analysts

Barclays - Etzer Darout

Bryan Garnier - Oscar Haffen-Lamm

Citizens Bank - Silvan Tuerkcan

Clear Street - Bill Maughan

Goldman Sachs - Salveen Richter

Jefferies - Amin Makarem

Kempen - Sebastiaan van der Schoot

Oddo BHF - Martial Descoutures

RW Baird - Jack Allen

Wells Fargo – Yanan Zhu

Cellectis contact information

Arthur Stril, Chief Financial Officer & Chief Business Officer

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89